COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
FOLLOW-COVID is an observational longitudinal follow-up study of adults with COVID-19. The researchers propose to analyse routine clinical data with linkage to retrospective and prospective health and
Sponsors
NHS Tayside
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Previous clinical (only if hospitalised) or microbiological (if hospitalised or non-hospitalised) diagnosis of COVID-19 disease 2. Aged >18 years
Exclusion criteria
Exclusion criteria: 1. Unable to give informed consent 2. Participation is not in the interests of the patient as determined by the investigator (e.g. palliative care) 3. If an individual has any symptoms compatible with current COVID-19 (as per the Health Protection Scotland Guidelines relevant at that time) 4. Currently isolated following a contact with COVID-19 5. Has had an upper respiratory tract infection in the preceding 14 days 6. Nasal brushings only: Patient has a history of significant epistaxis or is anti-coagulated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. A description of the early longitudinal changes in the airway epithelial microbiome and mycobiome using radiological and clinical note review at 3-6 months post-COVID-19 2. Recovery of symptoms post-COVID as self-defined by the patient at 3-6 months post-COVID-19 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. A detailed description of the early (3-6 months) regenerating ultrastructural changes in the nasal airway epithelium measured using a combination of video microscopy, electron microscopy, and cell culture techniques, in a spectrum of patients recovering from COVID-19 at 3-6 months post-COVID-19 2. Assessments of microvascular and macrovascular endothelial function, arterial stiffness, vascular inflammation, and fat metabolites in the 3-6 months following severe and non-severe COVID-19 measured using non-invasive techniques; these can be linked to inflammatory intravascular gene expression in PBMCs and whole blood; at 3-6 months post-COVID-19 3. A description of neutrophil function in patients recovering from severe COVID-19 pneumonia, including those with ARDS using radiological and clinical note review at 3-6 months post-COVID-19 4. Linking with the SCI-Diabetes database to obtain a comprehensive analysis of the impact of COVID-19 on diabetes care in affected patients and linking this to changes in serum metabolic biomarkers obtained 3-6 months following COVID-19 5. Long-term assessment of healthcare utilisation measured using electronically linked health care records, and phone interviews, and linking these outcomes with the work streams described above, and with biomarker discovery from stored samples, initially over 5 years and up to 25 years | — |
Countries
United Kingdom
Contacts
Public ContactStephanie Gallant
Outcome results
None listed